Changes in biochemical laboratory investigation in patients treated with constant infusion recombinant interleukin-2.
Eight patients with metastatic hypernephroma were treated with constant infusion recombinant Interleukin-2 (rIL-2), changes in renal and hepatic function and protein levels were monitored during 2 cycles of treatment. The rIL-2 infusion caused a reversible fall in ures and a non-reversible rise in creatinine. Liver function tests (bilirubin, ALT, ALP and GGT) rose during rIL-2 treatment and had returned to pretreatment levels 3 weeks after the last day of rIL-2. There was also a reversible fall in serum protein levels during rIL-2 infusion. Although constant infusion rIL-2 ameliorated much of the severe toxicities usually seen with high-dose bolus rIL-2, the non-reversible rise in serum creatinine levels is not a previously reported feature of rIL-2 therapy.
Ubhi
S S
SS
Department of Surgery, General Hospital, Leicester, U.K.
Horsburgh
T
T
Veitch
P S
PS
Bell
P R
PR
D000368:Aged; D000410:Alanine Transaminase / Q000097:blood; D000469:Alkaline Phosphatase / Q000097:blood; D001663:Bilirubin / Q000097:blood; D002292:Carcinoma, Renal Cell / Q000097:blood* / Q000628:therapy; D003404:Creatinine / Q000097:blood; D005260:Female; D006801:Humans; D007376:Interleukin-2 / Q000627:therapeutic use*; D007680:Kidney Neoplasms / Q000097:blood* / Q000628:therapy; D008297:Male; D008875:Middle Aged; D011994:Recombinant Proteins / Q000627:therapeutic use; D014508:Urea / Q000097:blood
D007376:Interleukin-2; D011994:Recombinant Proteins; D014508:Urea; D003404:Creatinine; D000410:Alanine Transaminase; D000469:Alkaline Phosphatase; D001663:Bilirubin